Regenerative Medicine Market by Product (Cell Therapies (Autologous, Allogenic), Stemcell Therapy, Tissue-engineering, Gene Therapy), Application (Wound Care, Musculoskeletal, Oncology, Dental, Ocular), Geography - Global Forecast to 2025
[167 Pages Report] The global regenerative medicine market is expected to reach USD 17.9 billion by 2025 from USD 8.5 billion in 2020, at a CAGR of 15.9%. Market growth is driven by rising investments in regenerative medicine research, and the growing pipeline of regenerative medicine products, and the increase in prevalence of chronic diseases, genetic disorders, and cancer.
To know about the assumptions considered for the study, Request for Free Sample Report
OVID-19 Impact on Global Regenerative medicine market
COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. The World Health Organization (WHO) declared COVID-19 as a pandemic on March 11, 2020. This pandemic has disrupted growth in many economies across various domains. The COVID-19 outbreak will impact the regenerative medicine market in the initial phase of the forecast period. Due to nationwide lockdowns, denied wound care services, cancelled or postponed elective surgeries, and increasing skin injuries in COVID-19 medical care providers, the regenerative medicine market is expected to register a certain decline during the forecast period. However, during the latter half of the forecast period, the demand for regenerative medicine products is expected to rise drastically.
Market Dynamics
Driver: Growing prevalence of chronic diseases, genetic disorders, and cancer
The incidence and prevalence of chronic diseases such as CVD, cancer, diabetes, ulcers, and genetic disorders such as cystic fibrosis have increased significantly across the globe, over the last few decades. The increased incidence and complexity of wounds such as infections, ulcerations (leg or foot ulcers), and surgical wounds, can be a result of diabetes and obesity, which will require treatments and incur exorbitant medical expenses.
Opportunity: Implementation of the 21st Century Cures Act
The 21st Century Cures Act was signed into law in the US in December 2016. Among other objectives, to advance regenerative medicine research and medical innovation this new law has been enacted and covers various provisions that may impact the approval and development of several products in the coming years.
Restraint: High cost of cell and gene therapies
Patients suffering from terminal illnesses and serious disorders requires cell and gene therapies which represent a significant scientific and medical advancement. These therapies are helping to transform how diseases are treated and potentially cured. Furthermore, such therapies will eventually enable doctors and medical professionals to infuse genes/cells via injectable means in order to avoid a series of drugs and multiple surgeries in patients. However, despite the fact of these therapies being lifesavers and more effective compared to the traditional treatments, the response in terms of demand for these therapies is less compared to the anticipation. This can be attributed to the high costs of these therapies and difficulty in obtaining reimbursements and coverage for these therapies.
Tissue-engineered products segment accounted for the largest share of the regenerative medicine market, by product, in 2019
Based on products, the regenerative medicine market is segmented into tissue-engineered products, cell therapies, gene therapies, and progenitor and stem cell therapies. The tissue-engineered products segment accounted for the largest share in the regenerative medicine market in 2019. The rising funding for the R&D of regenerative medicine products and therapies, and the increasing adoption of tissue-engineered products for the treatment of chronic wounds and musculoskeletal disorders are the major factors driving the growth of this segment.
Musculoskeletal segment accounted for largest share in the market, by application, in 2019
Based on applications, the regenerative medicine market is segmented into musculoskeletal disorders, wound care, oncology, ocular disorders, dental, and other applications. In 2019, the musculoskeletal disorders segment accounted for the largest market share. This can be attributed to the rise in geriatric population, increasing number of stem cell research projects, and increase in prevalence of orthopedic diseases.
North America is the largest regional market for regenerative medicine market
The global regenerative medicine market is segmented into four major regions, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2019, North America accounted for the largest share in the regenerative medicine market. The growth in the North American regenerative medicine market can be attributed to the expansion of the healthcare sector, and the higher adoption of stem cell therapy and cell immunotherapies for the treatment of cancer and chronic diseases, and rise in stem cell banking, tissue engineering, and drug discovery in the region.
To know about the assumptions considered for the study, download the pdf brochure
Some key players in the regenerative medicine market (2020- 2025)
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
Request Sample Scope of the Report
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
|
Report Metric |
Details |
|
Market size available for years |
20182025 |
|
Base year considered |
2019 |
|
Forecast period |
20202025 |
|
Forecast units |
Value (USD) |
|
Segments covered |
Product, application, and region |
|
Geographies covered |
North America, Europe, Asia Pacific, and Rest of the Wo |
|
Companies covered |
3M (US), Allergan plc (Ireland), Amgen, Inc. (US), Aspect Biosystems (Canada), bluebird bio (US), Kite Pharma (US), Integra LifeSciences Holdings Corporation (US), MEDIPOST Co., Ltd. (South Korea), Medtronic plc (Ireland), Anterogen Co., Ltd. (South Korea), MiMedx Group (US), Misonix (US), Novartis AG (Switzerland), Organogenesis Inc. (US), Orthocell Limited (Australia), Corestem, Inc. (South Korea), Spark Therapeutics (US), APAC Biotech (India), Shenzhen Sibiono GeneTech Co., Ltd. (China), Smith & Nephew plc (UK), Stryker Corporation (US), Takeda Pharmaceutical Company Limited (Japan), Tego Science (South Korea), Vericel Corporation (US), and Zimmer Biomet (US). |
This report categorizes the regenerative medicine market into the following segments and subsegments:
By Product
- Tissue-engineered Products
- Cell Therapies
- Autologous Therapies
- Allogenic Therapies
- Gene Therapies
- Progenitor & Stem Cell Therapies
By Application
- Musculoskeletal
- Oncology
- Wound Care
- Dental
- Ocular
- Other Applications
By Region
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Rest of Europe
- Asia Pacific
- Japan
- China
- Australia
- Rest of Asia Pacific
- Rest of the World
Recent Developments
- In February 2020, Integra Lifesciences (US) launched AmnioExcel Plus Placental allograft membrane.
- In November 2019, Stryker Corporation (US) acquired Wright Medical (US) to strengthen its product portfolio.
- In March 2019, Smith & Nephew (UK) acquired Osiris Therapeutics (US) to strengthen its product portfolio.
Frequently Asked Questions (FAQ):
What are the recent trends affecting the regenerative medicine market?
Recent trends affecting the regenerative medicine market are: COVID-19 outbreak, ririsng skin diseases and wounds in doctos and nurse using PPE kits 2 and 3 for COVID-19 duty; increasing adotpion in emerging economies and rising geriatric population; and cancellations of elective surgeries across the globe.
Who are the key players in the market, and how intense is the competition?
The key players in this market are: 3M (US), Allergan plc (Ireland), Amgen, Inc. (US), Aspect Biosystems (Canada), bluebird bio (US), Kite Pharma (US), Integra LifeSciences Holdings Corporation (US), MEDIPOST Co., Ltd. (South Korea), Medtronic plc (Ireland), Anterogen Co., Ltd. (South Korea), MiMedx Group (US), Misonix (US), Novartis AG (Switzerland), Organogenesis Inc. (US), Orthocell Limited (Australia), Corestem, Inc. (South Korea), Spark Therapeutics (US), APAC Biotech (India), Shenzhen Sibiono GeneTech Co., Ltd. (China), Smith & Nephew plc (UK), Stryker Corporation (US), Takeda Pharmaceutical Company Limited (Japan), Tego Science (South Korea), Vericel Corporation (US), and Zimmer Biomet (US).
What are the key applications of regenerative medicine products?
These products are used in various applications like wound care, musculoskeletal disorders, dental disorders, dermatology, ocular diseases, gynaecology diseases amongst others.
Which region is lucrative for the regenerative medicine market?
The emerging economies in Asia Pacific region like China, Japan, Australia will be the lucrative markets for regenerative medicine products. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 24)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
FIGURE 1 INCLUSIONS & EXCLUSIONS
1.2.1 MARKETS COVERED
1.2.2 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS
1.6 REPORT COMPARISON WITH THE MARCH 2019 EDITION
1.6.1 SUMMARY OF CHANGES
1.6.2 LIMITATIONS OF THE CURRENT EDITION
2 RESEARCH METHODOLOGY (Page No. - 29)
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
FIGURE 4 REGENERATIVE MEDICINE MARKET: BOTTOM-UP APPROACH
FIGURE 5 REGENERATIVE MEDICINE MARKET: BOTTOM-UP APPROACH: SEGMENTAL REVENUE ESTIMATION- TISSUE ENGINEERING
2.2.2 TOP-DOWN APPROACH
FIGURE 6 REGENERATIVE MEDICINE MARKET: TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.4 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY (Page No. - 37)
FIGURE 8 REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2020 VS. 2025 (USD MILLION)
FIGURE 9 REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2020 VS. 2025 (USD MILLION)
FIGURE 10 REGENERATIVE MEDICINE MARKET, BY REGION, 2020 VS. 2025 (USD MILLION)
4 PREMIUM INSIGHTS (Page No. - 40)
4.1 REGENERATIVE MEDICINE MARKET OVERVIEW
FIGURE 11 GROWING INVESTMENTS IN REGENERATIVE MEDICINE RESEARCH TO DRIVE MARKET GROWTH DURING THE FORECAST PERIOD
4.2 CELL THERAPIES MARKET, BY TYPE, 2020 VS. 2025 (USD MILLION)
FIGURE 12 AUTOLOGOUS CELL THERAPIES TO DOMINATE THE REGENERATIVE MEDICINE MARKET IN THE FORECAST PERIOD
4.3 REGENERATIVE MEDICINE MARKET SHARE, BY APPLICATION, 2020 VS. 2025
FIGURE 13 MUSCULOSKELETAL DISORDERS IS THE LARGEST APPLICATION SEGMENT OF THE REGENERATIVE MEDICINE MARKET
4.4 REGENERATIVE MEDICINE MARKET, BY REGION, 2020−2025
FIGURE 14 NORTH AMERICA TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 43)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 15 REGENERATIVE MEDICINE MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
5.2.1 DRIVERS
5.2.1.1 Rising prevalence of chronic diseases, genetic disorders, and cancer
FIGURE 16 INCIDENCE OF DIABETES, BY REGION, 2015 VS. 2040 (MILLION CASES)
TABLE 1 CANCER INCIDENCE AND MORTALITY, BY REGION, 20122035
TABLE 2 OBESITY-ASSOCIATED DEATH RATE (%), BY COUNTRY, 2017
5.2.1.2 Rising investments in regenerative medicine research
TABLE 3 TOTAL FUNDING, BY SOURCE TYPE, 20162019 (USD MILLION)
TABLE 4 FUNDING FROM CORPORATE PARTNERSHIPS, 20182019 (USD MILLION)
TABLE 5 FUNDRAISING THROUGH PUBLIC OFFERINGS (IPO & FOLLOW-ONS), 20182019 (USD MILLION)
TABLE 6 FUNDING FOR REGENERATIVE MEDICINE RESEARCH BY THE NIH UNDER THE 21ST CENTURY CURES ACT, 20172019 (USD BILLION)
TABLE 7 CALIFORNIA INSTITUTE OF REGENERATIVE MEDICINE FUNDING FOR REGENERATIVE MEDICINE RESEARCH (2017)
5.2.1.3 Growing pipeline of regenerative medicine products
TABLE 8 NUMBER OF COMPANIES OPERATING IN THE REGENERATIVE MEDICINE MARKET, BY REGION, 20162018
TABLE 9 NUMBER OF CLINICAL TRIALS IN THE REGENERATIVE MEDICINE MARKET, BY CLINICAL PHASE, 2018 VS. 2019
TABLE 10 NUMBER OF M&A TRANSACTIONS, 20162019 (USD MILLION)
5.2.2 RESTRAINTS
5.2.2.1 Ethical concerns related to the use of embryonic stem cells in research & development
5.2.2.2 High cost of cell and gene therapies
5.2.3 OPPORTUNITIES
5.2.3.1 Implementation of the 21st Century Cures Act
5.2.3.2 Rising demand for organ transplantations
5.3 IMPACT OF THE COVID-19 PANDEMIC ON THE REGENERATIVE MEDICINE MARKET
6 REGENERATIVE MEDICINE MARKET, BY PRODUCT (Page No. - 53)
6.1 INTRODUCTION
TABLE 11 FUNDING FOR REGENERATIVE MEDICINE PRODUCTS, 2019 (USD BILLION)
TABLE 12 NUMBER OF CLINICAL TRIALS IN THE REGENERATIVE MEDICINE MARKET, 2018 VS. 2019
TABLE 13 NEW PRODUCT APPROVALS IN THE REGENERATIVE MEDICINE MARKET, 2018-2020
TABLE 14 REGENERATIVE MEDICINE MARKET: PRODUCT PIPELINE (2019)
TABLE 15 REGENERATIVE MEDICINE MARKET, BY PRODUCT, 20182025 (USD MILLION)
6.2 TISSUE-ENGINEERED PRODUCTS
6.2.1 RISING PREVALENCE OF CHRONIC WOUNDS TO DRIVE THE MARKET GROWTH
TABLE 16 EXAMPLES OF COMMERCIALIZED TISSUE-ENGINEERED PRODUCTS
TABLE 17 TISSUE-ENGINEERED PRODUCTS MARKET, BY REGION, 20182025 (USD MILLION)
TABLE 18 NORTH AMERICA: TISSUE-ENGINEERED PRODUCTS MARKET, BY COUNTRY, 20182025 (USD MILLION)
TABLE 19 EUROPE: TISSUE-ENGINEERED PRODUCTS MARKET, BY COUNTRY, 20182025 (USD MILLION)
TABLE 20 APAC: TISSUE-ENGINEERED PRODUCTS MARKET, BY COUNTRY, 20182025 (USD MILLION)
6.3 CELL THERAPIES
TABLE 21 COMMERCIALIZED CELL THERAPIES AVAILABLE IN THE MARKET
TABLE 22 CELL THERAPIES MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 23 CELL THERAPIES MARKET, BY REGION, 20182025 (USD MILLION)
TABLE 24 NORTH AMERICA: CELL THERAPIES MARKET, BY COUNTRY, 20182025 (USD MILLION)
TABLE 25 EUROPE: CELL THERAPIES MARKET, BY COUNTRY, 20182025 (USD MILLION)
TABLE 26 APAC: CELL THERAPIES MARKET, BY COUNTRY, 20182025 (USD MILLION)
6.3.1 AUTOLOGOUS THERAPIES
6.3.1.1 Autologous therapies segment to register the highest growth in the cell therapies market
TABLE 27 EXAMPLES OF COMMERCIALIZED AUTOLOGOUS CELL THERAPIES
TABLE 28 AUTOLOGOUS THERAPIES MARKET, BY REGION, 20182025 (USD MILLION)
TABLE 29 NORTH AMERICA: AUTOLOGOUS THERAPIES MARKET, BY COUNTRY, 20182025 (USD MILLION)
TABLE 30 EUROPE: AUTOLOGOUS THERAPIES MARKET, BY COUNTRY, 20182025 (USD MILLION)
TABLE 31 APAC: AUTOLOGOUS THERAPIES MARKET, BY COUNTRY, 20182025 (USD MILLION)
6.3.2 ALLOGENEIC THERAPIES
6.3.2.1 Rising incidence of chronic conditions to drive the market growth
TABLE 32 EXAMPLES OF COMMERCIALIZED ALLOGENEIC CELL THERAPIES
TABLE 33 ALLOGENEIC THERAPIES MARKET, BY REGION, 20182025 (USD MILLION)
TABLE 34 NORTH AMERICA: ALLOGENEIC THERAPIES MARKET, BY COUNTRY, 20182025 (USD MILLION)
TABLE 35 EUROPE: ALLOGENEIC THERAPIES MARKET, BY COUNTRY, 20182025 (USD MILLION)
TABLE 36 APAC: ALLOGENEIC THERAPIES MARKET, BY COUNTRY, 20182025 (USD MILLION)
6.4 GENE THERAPIES
6.4.1 GROWING NUMBER OF CANCER CASES TO DRIVE MARKET GROWTH
TABLE 37 EXAMPLES OF COMMERCIALIZED GENE THERAPIES
TABLE 38 GENE THERAPIES MARKET, BY REGION, 20182025 (USD MILLION)
TABLE 39 NORTH AMERICA: GENE THERAPIES MARKET, BY COUNTRY, 20182025 (USD MILLION)
TABLE 40 EUROPE: GENE THERAPIES MARKET, BY COUNTRY, 20182025 (USD MILLION)
TABLE 41 APAC: GENE THERAPIES MARKET, BY COUNTRY, 20182025 (USD MILLION)
6.5 PROGENITOR & STEM CELL THERAPIES
6.5.1 GROWING PRODUCT PIPELINE TO SUPPORT THE GROWTH OF THIS SEGMENT
TABLE 42 EXAMPLES OF COMMERCIALIZED PROGENITOR & STEM CELL THERAPIES
TABLE 43 PROGENITOR & STEM CELL THERAPIES MARKET, BY REGION, 20182025 (USD MILLION)
TABLE 44 NORTH AMERICA: PROGENITOR & STEM CELL THERAPIES MARKET, BY COUNTRY, 20182025 (USD MILLION)
TABLE 45 EUROPE: PROGENITOR & STEM CELL THERAPIES MARKET, BY COUNTRY, 20182025 (USD MILLION)
TABLE 46 APAC: PROGENITOR & STEM CELL THERAPIES MARKET, BY COUNTRY, 20182025 (USD MILLION)
7 REGENERATIVE MEDICINE MARKET, BY APPLICATION (Page No. - 71)
7.1 INTRODUCTION
TABLE 47 NUMBER OF CLINICAL TRIALS FOR REGENERATIVE MEDICINE PRODUCTS, BY APPLICATION, 2018 VS. 2019
TABLE 48 REGENERATIVE MEDICINE MARKET, BY APPLICATION, 20182025 (USD MILLION)
7.2 MUSCULOSKELETAL DISORDERS
7.2.1 INCREASING PREVALENCE OF ORTHOPEDIC DISORDERS TO DRIVE THE GROWTH OF THIS APPLICATION SEGMENT
TABLE 49 REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 20182025 (USD MILLION)
TABLE 50 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 20182025 (USD MILLION)
TABLE 51 EUROPE: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 20182025 (USD MILLION)
TABLE 52 APAC: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 20182025 (USD MILLION)
7.3 ONCOLOGY
7.3.1 INCREASING INCIDENCE OF CANCER TO SUPPORT MARKET GROWTH
TABLE 53 NUMBER OF PATIENTS, BY TYPE OF CANCER, 20122030
TABLE 54 INDICATIVE LIST OF FEW COMMERCIALIZED REGENERATIVE CELL THERAPIES FOR THE TREATMENT OF CANCER
TABLE 55 REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY REGION, 20182025 (USD MILLION)
TABLE 56 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 20182025 (USD MILLION)
TABLE 57 EUROPE: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 20182025 (USD MILLION)
TABLE 58 APAC: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 20182025 (USD MILLION)
7.4 WOUND CARE
7.4.1 RISING PREVALENCE OF CHRONIC CONDITIONS TO DRIVE THE GROWTH OF THIS SEGMENT
TABLE 59 REGENERATIVE MEDICINE PRODUCTS COMMERCIALIZED FOR THE TREATMENT OF ACUTE & CHRONIC WOUNDS
TABLE 60 REGENERATIVE MEDICINE MARKET FOR WOUND CARE, BY REGION, 20182025 (USD MILLION)
TABLE 61 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR WOUND CARE, BY COUNTRY, 20182025 (USD MILLION)
TABLE 62 EUROPE: REGENERATIVE MEDICINE MARKET FOR WOUND CARE, BY COUNTRY, 20182025 (USD MILLION)
TABLE 63 APAC: REGENERATIVE MEDICINE MARKET FOR WOUND CARE, BY COUNTRY, 20182025 (USD MILLION)
7.5 DENTAL
7.5.1 RISING INCIDENCE OF ORAL DISORDERS TO DRIVE THE MARKET GROWTH
TABLE 64 REGENERATIVE MEDICINE MARKET FOR DENTAL APPLICATIONS, BY REGION, 20182025 (USD MILLION)
TABLE 65 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR DENTAL APPLICATIONS, BY COUNTRY, 20182025 (USD MILLION)
TABLE 66 EUROPE: REGENERATIVE MEDICINE MARKET FOR DENTAL APPLICATIONS, BY COUNTRY, 20182025 (USD MILLION)
TABLE 67 APAC: REGENERATIVE MEDICINE MARKET FOR DENTAL APPLICATIONS, BY COUNTRY, 20182025 (USD MILLION)
7.6 OCULAR DISORDERS
7.6.1 RISING PRODUCT APPROVALS TO DRIVE MARKET GROWTH
TABLE 68 REGENERATIVE MEDICINE MARKET FOR OCULAR DISORDERS, BY REGION, 20182025 (USD MILLION)
TABLE 69 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR OCULAR DISORDERS, BY COUNTRY, 20182025 (USD MILLION)
TABLE 70 EUROPE: REGENERATIVE MEDICINE MARKET FOR OCULAR DISORDERS, BY COUNTRY, 20182025 (USD MILLION)
TABLE 71 APAC: REGENERATIVE MEDICINE MARKET FOR OCULAR DISORDERS, BY COUNTRY, 20182025 (USD MILLION)
7.7 OTHER APPLICATIONS
TABLE 72 REGENERATIVE MEDICINE MARKET FOR OTHER APPLICATIONS, BY REGION, 20182025 (USD MILLION)
TABLE 73 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 20182025 (USD MILLION)
TABLE 74 EUROPE: REGENERATIVE MEDICINE MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 20182025 (USD MILLION)
TABLE 75 APAC: REGENERATIVE MEDICINE MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 20182025 (USD MILLION)
8 REGENERATIVE MEDICINE MARKET, BY REGION (Page No. - 88)
8.1 INTRODUCTION
TABLE 76 NUMBER OF PLAYERS IN THE REGENERATIVE MEDICINE MARKET, BY REGION, 2018 VS. 2019
TABLE 77 NUMBER OF CLINICAL TRIALS FOR REGENERATIVE MEDICINE, BY REGION (2019)
TABLE 78 REGENERATIVE MEDICINE MARKET, BY REGION, 20182025 (USD MILLION)
8.2 NORTH AMERICA
FIGURE 17 NORTH AMERICA: REGENERATIVE MEDICINE MARKET SNAPSHOT
TABLE 79 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 20182025 (USD MILLION)
TABLE 80 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 81 NORTH AMERICA: CELL THERAPIES MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 82 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 20182025 (USD MILLION)
8.2.1 US
8.2.1.1 Growing product pipeline to drive the market in the US
TABLE 83 PRODUCTS ANTICIPATED FOR APPROVALS IN THE US IN 2020
TABLE 84 PRODUCTS ANTICIPATED FOR FILINGS IN THE US IN 2020
TABLE 85 US: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 86 US: CELL THERAPIES MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 87 US: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 20182025 (USD MILLION)
8.2.2 CANADA
8.2.2.1 Increasing investments in R&D to drive market growth
TABLE 88 CANADA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 89 CANADA: CELL THERAPIES MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 90 CANADA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 20182025 (USD MILLION)
8.3 EUROPE
TABLE 91 EUROPE: RESEARCH FUNDING OVERVIEW (2017)
TABLE 92 PRODUCTS ANTICIPATED FOR APPROVALS IN EUROPE IN 2020
TABLE 93 PRODUCTS ANTICIPATED FOR FILINGS IN EUROPE IN 2020
TABLE 94 EUROPE: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 20182025 (USD MILLION)
TABLE 95 EUROPE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 96 EUROPE: CELL THERAPIES MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 97 EUROPE: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 20182025 (USD MILLION)
8.3.1 UK
8.3.1.1 Rising prevalence of chronic conditions to drive market growth in the UK
TABLE 98 UK: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 99 UK: CELL THERAPIES MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 100 UK: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 20182025 (USD MILLION)
8.3.2 GERMANY
8.3.2.1 Rising healthcare expenditure to propel market growth
TABLE 101 GERMANY: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 102 GERMANY: CELL THERAPIES MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 103 GERMANY: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 20182025 (USD MILLION)
8.3.3 FRANCE
8.3.3.1 Rising R&D expenditure, a major growth driver in France
TABLE 104 FRANCE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 105 FRANCE: CELL THERAPIES MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 106 FRANCE: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 20182025 (USD MILLION)
8.3.4 REST OF EUROPE
TABLE 107 ROE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 108 ROE: CELL THERAPIES MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 109 ROE: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 20182025 (USD MILLION)
8.4 ASIA PACIFIC
FIGURE 18 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET SNAPSHOT
TABLE 110 APAC: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 20182025 (USD MILLION)
TABLE 111 APAC: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 112 APAC: CELL THERAPIES MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 113 APAC: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 20182025 (USD MILLION)
8.4.1 JAPAN
8.4.1.1 Comparatively lenient regulations and rising geriatric population to drive market growth
TABLE 114 JAPAN: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 115 JAPAN: CELL THERAPIES MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 116 JAPAN: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 20182025 (USD MILLION)
8.4.2 CHINA
8.4.2.1 Favorable investments and government support to drive market growth in China
TABLE 117 CHINA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 118 CHINA: CELL THERAPIES MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 119 CHINA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 20182025 (USD MILLION)
8.4.3 AUSTRALIA
8.4.3.1 Strong research base and availability of funds to drive market growth
TABLE 120 AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 121 AUSTRALIA: CELL THERAPIES MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 122 AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 20182025 (USD MILLION)
8.4.4 ROAPAC
TABLE 123 ROAPAC: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 124 ROAPAC: CELL THERAPIES MARKET, BY TYPE, 20182025 (USD MILLION)
TABLE 125 ROAPAC: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 20182025 (USD MILLION)
8.5 REST OF THE WORLD
TABLE 126 ROW: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 20182025 (USD MILLION)
TABLE 127 ROW: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 20182025 (USD MILLION)
9 COMPETITIVE LANDSCAPE (Page No. - 117)
9.1 OVERVIEW
FIGURE 19 KEY DEVELOPMENTS IN THE REGENERATIVE MEDICINE MARKET (JANUARY 2017 AUGUST 2020)
9.2 CELL THERAPY MARKET SHARE ANALYSIS
FIGURE 20 CELL THERAPY MARKET SHARE ANALYSIS, BY KEY PLAYER, 2019
9.3 GENE THERAPY MARKET SHARE ANALYSIS
FIGURE 21 GENE THERAPY MARKET SHARE ANALYSIS, BY KEY PLAYER, 2019
9.4 TISSUE ENGINEERING MARKET RANKING
FIGURE 22 TISSUE ENGINEERING MARKET RANKING, 2019
9.5 COMPETITIVE SCENARIO
9.5.1 PRODUCT LAUNCHES & REGULATORY APPROVALS
TABLE 128 PRODUCT LAUNCHES & REGULATORY APPROVALS (JANUARY 2017AUGUST 2020)
9.5.2 COLLABORATIONS
TABLE 129 COLLABORATIONS (JANUARY 2017AUGUST 2020)
9.5.3 ACQUISITIONS
TABLE 130 ACQUISITIONS (JANUARY 2017AUGUST 2020)
9.5.4 EXPANSIONS
TABLE 131 EXPANSIONS (JANUARY 2017AUGUST 2020)
10 COMPANY EVALUATION MATRIX AND COMPANY PROFILES (Page No. - 121)
10.1 COMPANY EVALUATION MATRIX DEFINITION AND METHODOLOGY
10.1.1 VENDOR INCLUSION CRITERIA
10.1.2 STARS
10.1.3 EMERGING LEADERS
10.1.4 PERVASIVE
10.1.5 PARTICIPANTS
FIGURE 23 REGENERATIVE MEDICINE MARKET: COMPETITIVE LEADERSHIP MAPPING, 2019
10.2 COMPANY EVALUATION MATRIX FOR START-UPS (2019)
10.2.1 PROGRESSIVE COMPANIES
10.2.2 RESPONSIVE COMPANIES
10.2.3 STARTING BLOCKS
10.2.4 DYNAMIC COMPANIES
FIGURE 24 REGENERATIVE MEDICINE MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS, 2019
10.3 COMPANY PROFILES
(Business overview, Products offered, Recent developments, SWOT analysis, MNM view)*
10.3.1 SMITH & NEPHEW PLC
FIGURE 25 SMITH & NEPHEW PLC: COMPANY SNAPSHOT (2019)
10.3.2 VERICEL CORPORATION
FIGURE 26 VERICEL CORPORATION: COMPANY SNAPSHOT (2019)
10.3.3 INTEGRA LIFESCIENCES HOLDINGS CORPORATION
FIGURE 27 INTEGRA LIFESCIENCES HOLDINGS CORPORATION: COMPANY SNAPSHOT (2019)
10.3.4 MIMEDX GROUP
FIGURE 28 MIMEDX GROUP: COMPANY SNAPSHOT (2019)
10.3.5 NOVARTIS AG
FIGURE 29 NOVARTIS: COMPANY SNAPSHOT (2019)
10.3.6 STRYKER CORPORATION
FIGURE 30 STRYKER CORPORATION: COMPANY SNAPSHOT (2019)
10.3.7 ORGANOGENESIS INC.
FIGURE 31 ORGANOGENESIS: COMPANY SNAPSHOT (2019)
10.3.8 MEDIPOST CO., LTD.
FIGURE 32 MEDIPOST CO., LTD.: COMPANY SNAPSHOT (2019)
10.3.9 3M GROUP
FIGURE 33 3M GROUP: COMPANY SNAPSHOT (2019)
10.3.10 MISONIX
FIGURE 34 MISONIX: COMPANY SNAPSHOT (2019)
10.3.11 ZIMMER BIOMET
FIGURE 35 ZIMMER BIOMET: COMPANY SNAPSHOT (2019)
10.3.12 MEDTRONIC PLC
FIGURE 36 MEDTRONIC PLC: COMPANY SNAPSHOT (2019)
10.3.13 AMGEN, INC.
FIGURE 37 AMGEN, INC.: COMPANY SNAPSHOT (2019)
10.3.14 ALLERGAN
FIGURE 38 ALLERGAN: COMPANY SNAPSHOT (2019)
10.3.15 TAKEDA PHARMACEUTICAL COMPANY LIMITED
FIGURE 39 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2019)
10.3.16 ORTHOCELL LTD.
10.3.17 TEGO SCIENCE, INC.
10.3.18 CORESTEM, INC.
10.3.19 ANTEROGEN CO., LTD.
10.3.20 BLUEBIRD BIO
10.3.21 SPARK THERAPEUTICS
10.3.22 KITE PHARMA
10.3.23 APAC BIOTECH
10.3.24 SHENZHEN SIBIONO GENETECH CO., LTD.
10.3.25 ASPECT BIOSYSTEMS
*Business overview, Products offered, Recent developments, SWOT analysis, MNM view might not be captured in case of unlisted companies.
11 APPENDIX (Page No. - 161)
11.1 INSIGHTS FROM INDUSTRY EXPERTS
11.2 DISCUSSION GUIDE
11.3 KNOWLEDGE STORE: MARKETSANDMARKETS SUBSCRIPTION PORTAL
11.4 AVAILABLE CUSTOMIZATIONS
11.5 RELATED REPORTS
11.6 AUTHOR DETAILS
This study involved four major activities in estimating the current size of the regenerative medicine market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for this study.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industrys value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the regenerative medicine market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry have been identified through extensive secondary research
- The revenues generated by leading players operating in the regenerative medicine market have been determined through primary and secondary research
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
To know about the assumptions considered for the study, Request for Free Sample Report
Data Triangulation
After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Report Objectives
- To define, describe, and forecast the regenerative medicine market based on product, application, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, and opportunities)
- To strategically analyze micromarketsΉ with respect to individual growth trends, prospects, and contributions to the overall regenerative medicine market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to four regions, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW)
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies²
- To track and analyze competitive developments such as product launches, partnerships, expansions, collaborations, and acquisitions in the regenerative medicine market
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the companys specific needs. The following customization options are available for this report:
Country Information
Regenerative medicine market size and growth rate estimates for counties in Rest of Europe, the Rest of Asia Pacific and Rest of the World
Company profiles
- Additional five company profiles of players operating in the regenerative medicine market
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Regenerative Medicine Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Regenerative Medicine Market